Growth Hormone Axis Explained: GHRH, Ghrelin, GH, and IGF-1

The growth hormone axis is not a simple chain in which one peptide switches growth on. It is a pulsatile endocrine network linking the hypothalamus, anterior pituitary, liver, and peripheral tissues. Growth hormone-releasing hormone (GHRH) stimulates release, somatostatin restrains it, ghrelin receptor signaling modifies it, and growth hormone (GH) and insulin-like growth factor 1 (IGF-1) feed information back into the system.

This architecture matters when interpreting peptide research. Sermorelin, CJC-1295, tesamorelin, ipamorelin, and hexarelin are often grouped together as GH secretagogues. They do not act at the same receptor, produce identical exposure patterns, or carry equivalent clinical evidence.

This guide explains the axis as a research system. It does not provide dosing, treatment, or sourcing guidance.

The growth hormone axis at a glance

The core sequence is:

1. Hypothalamic neurons release GHRH and somatostatin into the hypophyseal portal circulation.
2. GHRH stimulates, while somatostatin inhibits, GH secretion from pituitary somatotrophs.
3. Ghrelin and synthetic growth hormone secretagogues can amplify GH release through the growth hormone secretagogue receptor, GHS-R1a.
4. Circulating GH binds the growth hormone receptor (GHR) in the liver and other tissues.
5. Hepatic GHR signaling increases circulating IGF-1, while local GH action and tissue-derived IGF-1 produce additional effects.
6. GH and IGF-1 participate in negative feedback at the pituitary and hypothalamus.

flowchart TD
  A[Hypothalamus] -->|GHRH stimulates| B[Pituitary somatotroph]
  A -->|Somatostatin inhibits| B
  C[Ghrelin or GHS-R1a agonist] -->|Amplifies secretion| B
  B -->|Pulsatile GH release| D[Growth hormone receptor]
  D --> E[Liver]
  D --> F[Peripheral tissues]
  E -->|Circulating IGF-1| G[IGF-1 receptor signaling]
  F -->|Local IGF-1 and direct GH effects| G
  G -->|Negative feedback| A
  G -->|Negative feedback| B

The diagram is deliberately simplified. Nutrition, sleep, age, sex steroids, stress, insulin status, body composition, and disease can all change pulse amplitude or the response of target tissues.

Step 1: GHRH supplies the stimulatory signal

GHRH is synthesized by neurons concentrated in the hypothalamic arcuate nucleus. It reaches the anterior pituitary through portal vessels and binds the GHRH receptor on somatotrophs. GHRHR is a class B G protein-coupled receptor that primarily engages Gs, adenylyl cyclase, cyclic AMP, protein kinase A, and calcium-dependent exocytosis.

The immediate result is release of stored GH. Longer signaling also supports GH synthesis and somatotroph function. This is the receptor targeted by GHRH-related compounds:

• Sermorelin is based on the biologically active N-terminal portion of GHRH.
• CJC-1295 is a modified GHRH analog studied in short-acting and albumin-binding forms.
• Tesamorelin is a stabilized GHRH analog with clinical evidence and a specific FDA-approved indication.

These compounds share receptor class, but not pharmacokinetics. A short GHRH-like stimulus and a long-acting analog can expose the receptor and feedback system to very different temporal signals.

Step 2: Somatostatin sets the inhibitory gate

Somatostatin is not background noise. It is a primary organizer of pulsatile GH release. Hypothalamic somatostatin suppresses somatotroph secretion through Gi-coupled somatostatin receptors, reducing cyclic AMP and calcium-dependent exocytosis.

The balance between GHRH drive and somatostatin restraint helps explain why GH is released in peaks separated by low interpulse concentrations. A rise in GHRH activity is more likely to produce a large pulse when somatostatin tone is low. The same stimulatory input can produce a smaller response when inhibitory tone is high.

This gating creates an important distinction between stimulating endogenous secretion and administering GH itself. Secretagogues still depend on pituitary reserve and remain influenced by endogenous inhibition and feedback. Exogenous GH enters the circulation downstream of those release controls.

Human physiology reviews have described this reciprocal control for decades, while newer work continues to refine how hypothalamic GHRH neurons integrate metabolic and neural signals. Useful starting points include the somatostatin review indexed as PMID 1976218 and the 2025 review of hypothalamic GHRH indexed as PMID 39913072.

Step 3: Ghrelin receptor signaling forms a parallel input

Ghrelin is produced mainly in the stomach, but its endocrine role extends beyond hunger signaling. Acylated ghrelin activates GHS-R1a, a receptor expressed in the hypothalamus and pituitary. Synthetic growth hormone-releasing peptides also act through this receptor.

GHS-R1a signaling is mechanistically distinct from GHRHR signaling. It commonly engages Gq/11, phospholipase C, inositol trisphosphate, and intracellular calcium. The result can still be GH release, but the route to that endpoint differs.

Examples include:

• Ipamorelin, a selective GH secretagogue studied for GHS-R1a-mediated release
• Hexarelin, a potent synthetic secretagogue with a broader endocrine response profile in the published literature

GHRH and GHS-R1a inputs can interact synergistically because they converge on somatotroph secretion through partly complementary signaling mechanisms. Synergy does not establish improved clinical outcomes, safety, or an appropriate protocol. It is a mechanistic observation that must be separated from treatment claims.

For broader endocrine context around these interacting signals, see the endocrine system research overview.

Step 4: The pituitary releases GH in pulses

GH secretion varies across the day and is strongly pulsatile. Large pulses often occur after sleep onset, but the profile changes with age, sex, nutritional state, adiposity, physical activity, and sleep quality. Because concentrations can be low between pulses, a random serum GH value is difficult to interpret without clinical context.

Pulsatility is biologically relevant, not merely a measurement problem. Signal amplitude, duration, and interpulse recovery can change receptor activation and gene transcription. A sustained elevation therefore should not be assumed to reproduce the biology of discrete endogenous peaks.

Research on long-acting CJC-1295 illustrates the distinction. A controlled study in healthy adults reported prolonged GH and IGF-1 stimulation after CJC-1295 exposure (PMID 16352683). A related analysis found that detectable pulsatility persisted during continuous stimulation (PMID 17018654). Those findings show that prolonged GHRH analog exposure does not necessarily flatten every pulse. They do not establish long-term clinical benefit or equivalence to physiological secretion.

Step 5: GH activates its own receptor and signaling network

GH binds GHR, a cytokine receptor expressed in the liver and many peripheral tissues. Ligand-induced rearrangement of the receptor complex activates Janus kinase 2 (JAK2), followed by phosphorylation of STAT proteins, especially STAT5. MAPK and PI3K-Akt pathways can also participate depending on tissue and context.

The downstream effects fall into two broad categories:

• Direct GH effects: changes in substrate metabolism, including effects on lipolysis, glucose handling, and protein metabolism
• IGF-1-mediated effects: stimulation of hepatic and local IGF-1 production, followed by IGF-1 receptor signaling in responsive tissues

The growth hormone receptor pathway provides a focused map of GHR, JAK2, STAT5, and related signaling.

A frequent oversimplification is that GH acts only by increasing IGF-1. The somatomedin model remains useful, but GH also has direct tissue effects, and tissues can produce IGF-1 locally. The relative contribution depends on the organ, developmental stage, nutritional state, and endpoint being studied.

Step 6: IGF-1 carries and shapes the downstream signal

The liver is the main source of circulating IGF-1, but it is not the only source. Muscle, bone, and other tissues produce IGF-1 for local autocrine and paracrine signaling. IGF-1 binds IGF-1R, a receptor tyrosine kinase that activates PI3K-Akt and RAS-MAPK pathways.

Most circulating IGF-1 is bound to IGF-binding proteins. IGFBP-3 and the acid-labile subunit form a ternary complex that extends residence time and controls tissue availability. Total serum IGF-1 is therefore a more stable marker of integrated GH-axis activity than a random GH concentration, but it is not a perfect proxy for every GH pulse or local tissue response.

The IGF-1 signaling axis and mTOR signaling guide explain how IGF-1R signaling connects to cell survival, growth, and protein synthesis pathways.

Negative feedback prevents unchecked output

Endocrine axes regulate themselves. Rising IGF-1 can reduce further GH output through actions at the hypothalamus and pituitary. GH also participates in short-loop feedback. Somatostatin release may increase, GHRH drive may fall, and intracellular inhibitors such as suppressors of cytokine signaling can constrain GHR output.

This means reduced response during repeated stimulation can have more than one cause:

• less receptor availability or receptor uncoupling
• stronger somatostatin restraint
• GH or IGF-1 negative feedback
• altered pituitary hormone stores
• downstream signaling adaptation
• changes in sleep, energy balance, or metabolic state

The site’s receptor desensitization and cycling guide examines these mechanisms in greater depth. The evidence does not support a universal cycling rule across all GH-axis compounds.

Where common research compounds enter the axis

The table is a pathway map, not a ranking. A compound acting farther upstream is not automatically safer or more physiological. Half-life, exposure, receptor selectivity, population, endpoint, and evidence quality all matter.

How to interpret GH-axis studies

Distinguish secretion from clinical outcomes

A larger GH pulse or higher IGF-1 concentration is a pharmacodynamic finding. It does not by itself demonstrate improved body composition, tissue repair, function, or long-term health.

Identify the exact compound and formulation

“CJC-1295” may refer to preparations with materially different half-lives. Conclusions from an albumin-binding form should not be transferred automatically to a short-acting GHRH analog.

Check the sampling design

Sparse GH measurements can miss pulses and distort peak estimates. Dense serial sampling, deconvolution analysis, and integrated area-under-the-curve measurements answer different questions from a single blood draw.

Separate disease populations from healthy populations

Tesamorelin findings in HIV-associated lipodystrophy do not establish the same risk-benefit profile in healthy adults. Likewise, early pharmacology in healthy volunteers does not establish efficacy for a disease endpoint.

Treat long-term safety as its own evidence question

Short studies can measure GH and IGF-1 response without resolving glucose effects, edema, joint symptoms, antibody formation, or concerns related to sustained signaling. Lack of a detected event in a small trial is not proof of absence.

Key takeaways

The growth hormone axis is a feedback-controlled, pulsatile network. GHRH and somatostatin organize pituitary secretion. Ghrelin receptor signaling supplies a separate stimulatory input. GH then activates GHR in the liver and peripheral tissues, and part of that signal is relayed through circulating and local IGF-1.

For peptide research, receptor identity and exposure pattern are central. GHRH analogs and GHS-R1a agonists can converge on GH release without being interchangeable. Pharmacodynamic evidence that a compound raises GH or IGF-1 should not be presented as proof of clinical benefit.

The most defensible interpretation follows the full chain: compound identity, receptor target, pulse pattern, GH output, IGF-1 response, tissue endpoint, comparator, study population, and duration.

This guide is for scientific education only. It is not medical advice and does not recommend the use, dosing, or sourcing of any peptide or hormone.

Related Research

• Growth Hormone Receptor Pathway - GHR, JAK2, STAT5, and direct GH signaling
• IGF-1 signaling axis - IGF-1R, binding proteins, and downstream growth signaling
• Endocrine System Research Overview - broader context for hypothalamic, pituitary, and peripheral hormone feedback
• Sermorelin Research - short GHRH-fragment pharmacology
• CJC-1295 Research - modified GHRH analog evidence and formulation distinctions
• Tesamorelin Research - clinical and regulatory evidence for a stabilized GHRH analog
• Ipamorelin Research - selective GHS-R1a agonist research
• Peptide Receptor Desensitization and Cycling - adaptation, feedback, and exposure-pattern considerations